Guggenheim upgraded Johnson & Johnson to Buy from Neutral with a price target of $206, up from $167.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Kenvue Stock (KVUE) Under Watch as Trump Team Eyes Tylenol–Autism Link
- J&J says FDA approves SC induction regimen of Tremfya
- Johnson & Johnson Stock (JNJ) Gains on Early EU Nod for Drug to Treat Muscle-Weakening Disease
- Johnson & Johnson announces positive CHMP opinion of nipocalimab
- JNJ: TECVAYLI/DARZALEX FASPRO regimen shows positive results in study